Immune-related hepatitis (ICB-hepatitis) is diagnosed during checkpoint blockade therapy based on changes in Alanine-Aminotransferase (ALT), Aspartate-Aminotransferase (AST) and other indices of liver function following exclusion of alternative etiologies of hepatitis [8]. This evidence concerns the gene GPT and hepatitis A virus infection.